Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Quoin Pharmaceuticals ( (QNRX) ) just unveiled an announcement.
On July 3, 2025, Quoin Pharmaceuticals Ltd. announced that its Chief Financial Officer, Gordon Dunn, will be departing from the company later this year. Dunn will remain in his position until a successor is appointed, and a separation agreement is anticipated to be finalized and filed in the company’s future reports.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Average Trading Volume: 194,769
Technical Sentiment Signal: Sell
Current Market Cap: $5.22M
Find detailed analytics on QNRX stock on TipRanks’ Stock Analysis page.